Sermorelin Nasal Spray: Evidence & Limits

Sermorelin nasal spray is one of the easiest sells in the peptide market: a few sprays a day, no needles, no reconstitution, no sharps to dispose of. Compounding pharmacies and online clinics offer it as a convenient alternative to the nightly subcutaneous shot, often implying it delivers the same growth-hormone benefits. The pharmacology tells a more sober story. The nasal route does something genuinely interesting with peptides — but “something interesting” and “raises your growth hormone like the injection” are not the same claim, and for sermorelin specifically the human data point the wrong way for the systemic promise being made.

This article is about delivery route, not about whether GHRH peptides do anything at all. For the underlying evidence base, see our pillar guide to sermorelin's sleep and recovery evidence. Here the question is narrow and mechanical: if you spray sermorelin into your nose, does enough of it reach your bloodstream to stimulate the pituitary the way an injection does? We also cover the broader needle-free question — tablets and troches — in oral and sublingual sermorelin; the nasal route deserves its own look because, unlike the gut, the nose has a real and well-studied trick.

The nose's real trick — and why it doesn't help the way you'd hope

The nasal cavity is not just another mucous membrane. Because of the olfactory and trigeminal nerve pathways at the roof of the nose, some molecules can travel from the nasal lining directly toward the brain, partly bypassing the bloodstream. This “nose-to-brain” route is real: a landmark human study showed that several neuropeptides delivered intranasally raised their concentrations in cerebrospinal fluid (the fluid around the brain) without a matching rise in blood levels⁴. That is the foundation of an entire field of intranasal peptide research aimed at central-nervous-system targets⁵.

Read that finding carefully, because the marketing inverts it. Nose-to-brain delivery works precisely because the molecule reaches the brain side while staying low in the blood. But sermorelin's whole point is systemic: it needs to reach the pituitary and the GH/IGF-1 axis in the bloodstream to produce the body-composition, recovery, and metabolic effects people buy it for. A route optimized to move tiny amounts of peptide into the CNS while keeping blood levels low is, if anything, the opposite of what a systemic GHRH product needs. The nose is good at the wrong thing for this use case.

The most important data point: intranasal GHRH did not raise blood growth hormone

Here is the experiment that should anchor any honest discussion of sermorelin nasal spray. In a controlled human study, researchers gave GHRH (the parent hormone sermorelin is a fragment of) by two routes and watched plasma growth hormone. Given intravenously, GHRH raised plasma GH as expected. Given intranasally at 300 micrograms, the same hormone did not raise plasma GH at all¹. The nasal route simply failed to deliver a systemically meaningful dose to the GH axis.

That isn't an isolated result. The same research group found that intranasal GHRH could shift sleep architecture and other central endpoints — exactly the nose-to-brain pattern you'd predict, a small amount reaching the CNS — while again not behaving like a systemic GH-raising dose². And separate work on central GHRH signaling reinforces that the brain-side effects of nasal GHRH are real but distinct from raising circulating growth hormone³. So the closest, most direct human evidence we have for this exact molecule by this exact route says: nasal GHRH may touch the brain, but it does not move the bloodstream GH/IGF-1 system the way the injection does.

There is no published human pharmacokinetic study showing that any sermorelin nasal spray raises plasma growth hormone or IGF-1. Until one exists, the systemic claims made for nasal sermorelin rest on hope, not data.

Why peptides are so hard to push through the nose into the blood

The general obstacle is the same one that defeats oral peptides, just less extreme. The nasal mucosa has tight junctions between cells, peptide-degrading enzymes, and a mucociliary clearance system that sweeps anything you spray in toward the throat within minutes — shrinking the contact time. Large, water-loving peptides cross that barrier inefficiently. Reviews of intranasal peptide therapeutics are candid that, while the route is promising for CNS targets, getting reproducible systemic exposure of a peptide through the nose is an unsolved formulation challenge that typically requires permeation enhancers and careful engineering⁵. The same difficulty that holds optimized oral peptide drugs to roughly 1% bioavailability — enzymatic destruction plus a physical wall — applies, in milder form, at the nose⁸. Spraying a compounded peptide into your nostril does not bypass that physics; it just changes which barrier you're up against.

The nasal peptides that DO work prove the rule

It's fair to point out that some peptides genuinely work as nasal sprays — desmopressin and calcitonin among them — so why not sermorelin? The answer is in the fine print of the ones that succeeded. Desmopressin nasal spray is FDA-approved and effective, but its absolute bioavailability by the nasal route is only a fraction of a percent, which is exactly why it is dosed in micrograms and why a micro-dose nasal formulation had to be characterized in formal pharmacokinetic trials before use⁷. Desmopressin works needle-free not because the nose is efficient, but because the molecule is extraordinarily potent and precisely dosed from real PK data. The newer wave of intranasal peptide products in development for Alzheimer's and other CNS conditions tells the same story: they require purpose-built delivery systems and are still largely experimental⁶.

Sermorelin nasal spray has none of that scaffolding. It is compounded, not FDA-approved in any nasal form; there is no standardized formulation, no established bioavailability figure, and no human trial showing it raises the GH axis. The peptides that succeeded nasally did so with regulatory-grade dose control and molecule-specific engineering — precisely what a compounded sermorelin spray lacks.

A second problem stacked on the first: compounding quality

Even if you set absorption aside, nasal sermorelin inherits the quality uncertainty of all compounded peptides. Because there is no FDA-approved finished product, what's in the bottle isn't standardized. When researchers analyzed compounded and follow-on versions of peptide drugs against the originators, several contained less active peptide than the label claimed, along with new impurity profiles⁹. Stack that on a route whose bioavailability is already low and unmeasured, and you have two compounding unknowns multiplied together: how much sermorelin is actually in each spray, and how little of it actually crosses into your circulation. Neither number is verified for any consumer nasal sermorelin product — and the nasal form typically carries a 20–30% premium over the injectable, as we cover in our sermorelin cost breakdown.

The route that actually has positive human data

Every credible demonstration that sermorelin does anything to the GH/IGF-1 axis rests on it being injected. Nightly subcutaneous GHRH(1-29) raised growth hormone and IGF-1 in healthy elderly men¹⁰, and parenteral GHRH(1-29) is a validated provocative test of pituitary GH reserve¹¹. The contrast could hardly be cleaner: by injection, this peptide measurably moves the GH axis; by the nasal route, the parent hormone did not¹. If your goal is the systemic effect, the data live with the needle — which is why our dosing guide and injection how-to both deal with subcutaneous administration, the only route with supporting human evidence.

So is sermorelin nasal spray worth it?

Putting it together honestly:

• •The nasal route's real strength is nose-to-brain delivery of small amounts of peptide into the CNS while blood levels stay low⁴⁵ — the opposite of what a systemic GHRH product needs.
• •The most direct human experiment for this molecule showed intranasal GHRH did not raise plasma growth hormone, while intravenous GHRH did¹.
• •The nasal peptides that succeed (desmopressin, calcitonin) work despite tiny bioavailability because they are FDA-approved, micro-dosed, and PK-characterized⁷ — none of which is true of compounded sermorelin spray.
• •Compounded peptides vary in actual content versus label⁹, adding a second unknown.
• •The only route with positive human GH/IGF-1 data for GHRH(1-29) is subcutaneous injection¹⁰¹¹.

The bottom line: sermorelin nasal spray is a convenience product sold ahead of its evidence. There may be a future in nose-to-brain GHRH research for sleep or cognition specifically — the central effects are real and worth studying — but that is a different, unproven claim from “it works like the injection.” If a provider sells you a nasal spray as equivalent to the shot, ask for the human data showing it raises your IGF-1. As with oral and sublingual sermorelin, there isn't any yet. And if you've decided that prescribed, injected sermorelin is what you actually want, we rank the providers honestly on price and oversight in our guide to the best sermorelin providers.